|
1
|
Fishman SJ and Mulliken JB: Hemangiomas
and vascular malformations of infancy and childhood. Pediatr Clin
North Am. 40:1177–1200. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jacobs AH and Walton RG: The incidence of
birthmarks in the neonate. Pediatrics. 58:218–222. 1976.PubMed/NCBI
|
|
3
|
Amir J, Metzker A, Krikler R and Reisner
SH: Strawberry hemangioma in preterm infants. Pediatr Dermatol.
3:331–332. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holland KE and Drolet BA: Infantile
hemangioma. Pediatr Clin North Am. 57:1069–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grzesik P and Wu JK: Current perspectives
on the optimal management of infantile hemangioma. Pediatric Health
Med Ther. 8:107–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engels BM and Hutvagner G: Principles and
effects of microRNA-mediated post-transcriptional gene regulation.
Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Li P, Guo Z, Wang H and Pan W:
Downregulation of miR-382 by propranolol inhibits the progression
of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway. Int
J Mol Med. 39:757–763. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bertoni N, Pereira LM, Severino FE, Moura
R, Yoshida WB and Reis PP: Integrative meta-analysis identifies
microRNA-regulated networks in infantile hemangioma. BMC Med Genet.
17:42016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Venneti S, Boateng LA, Friedman JR,
Baldwin DA, Tobias JW, Judkins AR, Mourelatos Z and Lal P: MiRNA-9
and MiRNA-200a distinguish hemangioblastomas from metastatic clear
cell renal cell carcinomas in the CNS. Brain Pathol. 22:522–529.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang C, Huang J, Ma P and Yu G:
microRNA-143 acts as a suppressor of hemangioma growth by targeting
Bcl-2. Gene. 628:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chamorro-Jorganes A, Araldi E, Penalva LO,
Sandhu D, Fernández-Hernando C and Suárez Y: MicroRNA-16 and
microRNA-424 regulate cell-autonomous angiogenic functions in
endothelial cells via targeting vascular endothelial growth factor
receptor-2 and fibroblast growth factor receptor-1. Arterioscler
Thromb Vasc Biol. 31:2595–2606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakashima T, Jinnin M, Etoh T, Fukushima
S, Masuguchi S, Maruo K, Inoue Y, Ishihara T and Ihn H:
Down-regulation of mir-424 contributes to the abnormal angiogenesis
via MEK1 and cyclin E1 in senile hemangioma: Its implications to
therapy. PLoS One. 5:e143342010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling-in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho WC: MicroRNAs in cancer-from research
to therapy. Biochim Biophys Acta. 1805:209–217. 2010.PubMed/NCBI
|
|
23
|
Long XH, Mao JH, Peng AF, Zhou Y, Huang SH
and Liu ZL: Tumor suppressive microRNA-424 inhibits osteosarcoma
cell migration and invasion via targeting fatty acid synthase. Exp
Ther Med. 5:1048–1052. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu L, Ding GF, He C, Sun L, Jiang Y and
Zhu L: MicroRNA-424 is down-regulated in hepatocellular carcinoma
and suppresses cell migration and invasion through c-Myb. PLoS One.
9:e916612014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pallasch CP, Patz M, Park YJ, Hagist S,
Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J,
et al: miRNA deregulation by epigenetic silencing disrupts
suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Blood. 114:3255–3264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faraoni I, Laterza S, Ardiri D, Ciardi C,
Fazi F and Lo-Coco F: MiR-424 and miR-155 deregulated expression in
cytogenetically normal acute myeloid leukaemia: Correlation with
NPM1 and FLT3 mutation status. J Hematol Oncol. 5:262012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F,
Xie X, Zhou C and Lu W: Suppressed miR-424 expression via
upregulation of target gene Chk1 contributes to the progression of
cervical cancer. Oncogene. 32:976–987. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang L, Dai J, Li F, Cheng H, Yan D and
Ruan Q: The expression and function of miR-424 in infantile skin
hemangioma and its mechanism. Sci Rep. 7:118462017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29 6 Suppl 16:S15–S18. 2002.
View Article : Google Scholar
|
|
30
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Folkman J: Anti-angiogenesis: New concept
for therapy of solid tumors. Ann Surg. 175:409–416. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samant RS and Shevde LA: Recent advances
in anti-angiogenic therapy of cancer. Oncotarget. 2:122–134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bose D, Meric-Bernstam F, Hofstetter W,
Reardon DA, Flaherty KT and Ellis LM: Vascular endothelial growth
factor targeted therapy in the perioperative setting: Implications
for patient care. Lancet Oncol. 11:373–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang BH, Zheng JZ, Aoki M and Vogt PK:
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and
expression of vascular endothelial growth factor in endothelial
cells. Proc Natl Acad Sci USA. 97:pp. 1749–1753. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59 2
Suppl:S21–S26. 2004. View Article : Google Scholar
|
